Presentation highlights Blacksmith's novel chemistry platform for targeting metalloenzymes and FG-2101, a first-in-class non-hydroxamate LpxC inhibitor ...

From new payload linkers to artificial intelligence partnerships, advances in ADC pipelines push forward selective cancer therapies that minimize side effects.

Stem cells differentiated into brain and neural organoids may help scientists understand both brain development and ...

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its proprietary CDH17-targeting antibody-drug conjugate (ADC), 7MW4911, has received ...

A new study reveals that astrocyte-derived GABA, not neuronal activity, plays a central role in PTSD by impairing the brain’s ability to extinguish traumatic memories.

The Phase I trial of ENERGI-F705PD tablet was a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and ...

Aclaris Therapeutics announces positive top-line results from phase 2a clinical trial of ATI-2138: Wayne, Pennsylvania Friday, August 1, 2025, 14:00 Hrs [IST] Aclaris Therapeutics ...